Document text
Principal Investigator: Jeffrey Tornheim
Organization: JOHNS HOPKINS UNIVERSITY
Fiscal Year: 2024
Award: $639,787
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
Tuberculosis is the bacterial infection that kills the most people worldwide, especially in India, which has the
highest burden in of multidrug-resistant tuberculosis (MDR-TB) in the world. Delays in adequate treatment due
to slow diagnostic tests and the usual one-size-fits-all MDR-TB treatment strategy lead to additional drug
resistance, terrible treatment-associated side effects, and high mortality. Rapid next generation sequencing
(NGS) from uncultured samples is a novel diagnostic tool that can predict resistance and minimum inhibitory
concentration (MIC) ranges for MDR-TB within 2 days of presentation–weeks before culture-based susceptibility
tests provide results. NGS-predictions allow providers to tailor MDR-TB treatment and choose doses to target
specific drug levels at the start of treatment. Most MDR-TB drugs reach steady state within 2 weeks, so early
therapeutic drug monitoring (TDM) supported by direct observation of therapy could verify that predicted efficacy
targets are achieved as soon as possible, ensuring that patients get the right drugs at the right dose as early as
possible and before suffering side effects from poorly tailored treatment. This would be a dramatic improvement
over current culture-based methods of regimen selection, where results return 2 months later, if at all. Our clinical
site has previously enrolled ~800 participants with MDR-TB into cohort studies for longitudinal follow-up,
monitored participants for side effects and treatment outcomes, and developed on-site workflows for phenotypic
drug resistance, MIC testing, NGS from uncultured sputum, and plasma drug level testing of MDR-TB drugs.
Each of these tools is available at our site, but they are only employed sporadically, are rarely used in the same
patients, and have not been systematically analyzed for their relative contributions to patient outcomes. We will
conduct a single-site observational cohort study of 210 adult participants with pulmonary smear-positive,
rifampin-resistant TB to systematically evaluate the impact of a combination Baseline pRescription According to
Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS) for personalized
MDR-TB therapy as access to these tools expands. The specific aims of this proposal are to: 1) determine the
proportion of patients with MDR-TB in Mumbai, India with resistance-associated mutations that would prevent
treatment with moxifloxacin, linezolid, bedaquiline, clofazimine, or cycloserine using culture-free NGS; 2) identify
the proportion of cohort participants with MDR-TB that achieve model-derived steady-state plasma levels
meeting efficacy and toxicity targets; and 3) assess the time to final regimen, frequency of treatment-associated
side effects, time to culture conversion, and final outcome of cohort participants who complete culture-free NGS
and TDM. The results of this observational cohort will determine the combined benefit of these tools as they are
deployed at a referral center with clinical and laboratory expertise in complex drug resistance. These data will
describe the real-world outcomes of MDR-TB care using NGS and TDM for MDR-TB in a unique setting and will
inform the future application of these tools to improved strategies for personalized MDR-TB treatment worldwide.
Terms: <21+ years old><Active Follow-up><Adherence><Adult><Adult Human><Antitubercular Drugs><Assay><Bacterial Infections><Benemycin><Bioassay><Biological Assay><Blood Plasma><Bone Marrow Suppression><COVID-19><CV-19><Caring><Cell Phone><Cellular Phone><Cellular Telephone><Clinical><Collaborations><Communicable Diseases><Complex><Coronavirus Infectious Disease 2019><Cycloserine><Data><Development><Diagnostic tests><Disease><Disorder><Dose><Drug Kinetics><Drug Monitoring><Drug Resistance Tuberculosis><Drug Resistant TB><Drug Resistant Tuberculosis><Drug Targeting><Drug resistance><Drug resistance in tuberculosis><Drugs><ECG><EKG><Electrocardiogram><Electrocardiography><Enrollment><Ensure><Evaluation><Frequencies><Future><Genetic Alteration><Genetic Change><Genetic defect><Genotype><Goals><Guidelines><Hospitals><Hour><India><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Infrastructure><Injury to Liver><Laboratories><Lead><Linezolid><Long-term cohort><Long-term cohort study><Longitudinal cohort><Longitudinal cohort study><Longterm cohort><Longterm cohort study><Lung><Lung Respiratory System><Lung TB><Lung Tuberculosis><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MDR Tuberculosis><MDR-TB><MTB infection><Measures><Medication><Methods><Minimum Inhibitory Concentration measurement><Minimum Inhibitory Concentrations><Mobile Phones><Modeling><Molecular><Monitor><Moxifloxacin><Multi-Drug Resistant Tuberculosis><MultiDrug Resistance Tuberculosis><Multidrug-Resistant Tuberculosis><Mutation><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><NGS Method><NGS system><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Neuropathy><Oral><Outcome><Participant><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pb element><Persons><Pharmaceutical Preparations><Pharmacokinetics><Phenotype><Plasma><Plasma Serum><Predisposition><Preparation><Prospective, cohort study><Provider><Pulmonary TB><Pulmonary Tuberculosis><Recommendation><Regimen><Reporting><Resistance><Reticuloendothelial System, Serum, Plasma><Rifadin><Rifampicin><Rifampicin resistance><Rifampicin resistant><Rifampin><Rifampin resistance><Rifampin resistant><Rimactane><Safety><Sampling><Selection for Treatments><Severities><Sight><Site><Sputum><Strategic Planning><Susceptibility><TB drug resistance><TB drugs><TB infection><TB therapy><TB treatment><Test Result><Testing><Therapeutic><Time><Toxic effect><Toxicities><Transmission><Treatment outcome><Tuberculosis><United States National Institutes of Health><Validation><Vision><Work><Zyvox><active followup><adulthood><anti-TB drugs><anti-tuberculosis drugs><bacteria infection><bacterial disease><biomedical referral center><brass><clinical research site><clinical site><cohort><coronavirus disease 2019><coronavirus disease-19><coronavirus infectious disease-19><customized therapy><customized treatment><determine efficacy><developmental><diagnostic algorithm><diagnostic tool><disseminated TB><disseminated tuberculosis><drug detection><drug resistance in TB><drug resistant><drug resistant in tuberculosis><drug testing><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy outcomes><enroll><evaluate efficacy><examine efficacy><follow up><follow-up><followed up><followup><genome mutation><heavy metal Pb><heavy metal lead><hepatic damage><hepatic injury><iPhone><implementation tool><improved><improved outcome><individualized medicine><individualized patient treatment><individualized strategies><individualized therapeutic strategy><individualized therapy><individualized treatment><ineffective therapies><ineffective treatment><infection due to Mycobacterium tuberculosis><innovate><innovation><innovative><liver damage><liver injury><meeting><meetings><mortality><multidrug-resistant TB><neuropathic><new diagnostics><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation diagnostics><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel diagnostics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><observational cohort study><patient oriented outcomes><patient specific therapies><patient specific treatment><personalized strategies><pharmacokinetic model><preparations><prevent><preventing><prognostic assays><prognostic test><pulmonary><referral center><resistance to Drug><resistance to rifampicin><resistance to rifampin><resistant><resistant to Drug><resistant to rifampicin><resistant to rifampin><response to therapy><response to treatment><selection of treatment><side effect><smart phone><smartphone><tailored medical treatment><tailored therapy><tailored treatment><therapeutic response><therapy response><therapy selection><tool><transmission process><treat M. tuberculosis><treat Mtb><treat Mycobacterium tuberculosis><treat tb><treat tuberculosis><treatment response><treatment responsiveness><treatment selection><treatment strategy><trial comparing><tuberculosis drugs><tuberculosis infection><tuberculosis therapy><tuberculosis treatment><tuberculous spondyloarthropathy><unique treatment><validations><visual function>